Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Evercore ISI Group Downgrades Audentes Therapeutics to In-Line

Author: Benzinga Newsdesk | December 09, 2019 12:01pm
Evercore ISI Group downgrades Audentes Therapeutics (NASDAQ:BOLD) from Outperform to In-Line.

Posted In: BOLD